Colin C. Pritchard MD, PhD, presented “Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and Aggressiveness” for the Grand Rounds in Urology audience in January, 2020.
How to cite: Pritchard, Colin C. “Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and Aggressiveness” January, 2020. Accessed Nov 2024. https://dev.grandroundsinurology.com/molecular-insights-into-the-germline-for-prostate-cancer-initiation-progression-and-aggressiveness/
Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and Aggressiveness – Summary:
Colin C. Pritchard, MD, PhD, Director of the Genetics and the Solid Tumors Laboratory at the University of Washington, discusses how germline testing and next-generation sequencing (NGS) of tumors have become important for guiding prostate cancer diagnosis, treatment, and assessment of risk. He details DNA damage response (DDR) genes, including key pathways, potential risk factors, and general characteristics. He also discusses the role of molecular pathologists in testing samples, choosing methodology, and interpreting results.
This educational activity is based on a series of lectures on genetic testing for prostate cancer from the 2019 Philadelphia Prostate Cancer Consensus Conference. Further activities from this conference include:
Germline Predisposition for Prostate Cancer Among African American and Other Minorities: What Do We Know?
Prostate Cancer Screening & Genetic Testing: The NCCN Perspective
Current NCCN Recommendations for Prostate Cancer Genetic Testing
The Expanding World of Germline Testing for Prostate Cancer: Genetic Counseling Perspective
The Expanding World of Germline Testing for Prostate Cancer: A Clinical Trials Perspective
Current Prostate Cancer Genetic Testing Capabilities and Considerations
A Urologist’s Perspective on Germline Testing
Integration of Germline Testing in Prostate Cancer Screening
ABOUT THE AUTHOR
Dr. Pritchard is an Associate Professor of Genetics in the Department of Laboratory Medicine at the University of Washington (UW) in Seattle. He also serves as Head of the Genetics Division of Laboratory Medicine at UW Medicine, Director of Clinical Diagnostics for the Brotman Baty Institute for Precision Medicine, and Co-Director of the Genetics and Solid Tumors Laboratory at the University of Washington Medical Center, a facility that services the Seattle Cancer Care Alliance (SCCA). Dr. Pritchard also undertook his graduate and medical training at the University of Washington.
The Pritchard Laboratory focuses on oncology molecular diagnostics, particularly the source and utility of cell-free nucleic acid biomarkers in blood, and the development of innovative molecular diagnostics for the identification of DNA repair gene mutations that can guide therapeutic decision-making. His clinical work focuses on applications of next-generation sequencing gene panels for cancer risk assessment and precision treatment. He has led the development and implementation of the ColoSeq™ Lynch and Polyposis Syndrome Panel and UW-OncoPlex™ Cancer Gene Panel, both of which are in current clinical use for cancer patients and their families.
